Updated: Oct 20
Medically reviewed by ChinaCureLink Team
Table of Content
Why This Case Matters
For lung cancer patients with an EGFR mutation, treatment options increasingly depend on access — access to the latest targeted therapies, and access to hospitals equipped to use them. When those options run out at home, patients are often left searching for where else in the world that access exists.
Key Takeaways |
|
Patient Background
Rachel M. (alias) is a patient from New Zealand who was being treated for lung adenocarcinoma with an EGFR mutation in the public hospital system. She reached a point where no further treatment options remained available to her at home, and learned about the possibility of continuing treatment in China directly from another patient who had already gone through the experience.
The Care Team and Approach
Rachel traveled to a JCI-accredited hospital in China recognized for its non-invasive surgical and interventional techniques. There, her care was managed by a medical team she described as clear and thorough — taking the time to explain everything she wanted to understand — with nursing care she found exceptionally attentive. Coming from a public hospital system, she noted the shift to private, specialized care in China as a significant difference in how her treatment felt day to day.
Treatment Timeline/ Process
In New Zealand
Diagnosed with lung adenocarcinoma with an EGFR mutation
Treated within the public hospital system
Received platinum-based chemotherapy, administered as two distinct treatment courses
Reached a point where no further treatment options remained available locally
Learned of treatment access in China through word of mouth from another patient
In China
Admitted to a JCI-accredited hospital recognized for non-invasive surgical and interventional techniques
Started amivantamab, an EGFR-targeted therapy, as her disease called for a more targeted approach
Learned about sunvozertinib, another EGFR-targeted option available in China but not yet approved back home in New Zealand, Australia, Europe, or most other markets. Treatment costs in China also tend to run lower than private oncology pricing in the US, in line with the broader cost advantage patients often find when seeking specialized care there.
Outcome
Rachel's account reflects her experience of care and access rather than a documented clinical outcome. What her case illustrates clearly is a pattern increasingly common among EGFR-mutated lung cancer patients: targeted therapies approved and available in China aren't always accessible in a patient's home country, and that gap is often what drives the decision to seek care abroad.
How ChinaCureLink Can Help Patients to Access This Treatment
ChinaCureLink connects international patients with JCI-accredited hospitals in China offering access to the latest targeted oncology treatments, and coordinates the practical side of care abroad — medical record translation, specialist matching, treatment scheduling, and support from first inquiry through follow-up care. For patients whose home countries haven't yet approved the therapy their diagnosis calls for, that access can open a path forward that otherwise wouldn't exist.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
How can an international patient access sunvozertinib since it isn't approved in most countries?
Because sunvozertinib is only approved in China and the US, New Zealand patients typically need to travel and be treated directly at an approved hospital rather than obtaining the drug through their local pharmacy or oncologist. ChinaCureLink coordinates this process, from hospital matching through to treatment and follow-up.
How much does cancer treatment in China cost for international patients?
Costs vary widely depending on diagnosis, treatment type, and hospital, and typically include consultation, medication, and hospital stay. ChinaCureLink can provide a cost estimate specific to a patient's diagnosis and treatment plan after an initial case review.
How long does it take to arrange cancer treatment in China from New Zealand?
Timelines depend on how quickly medical records and test results can be shared and reviewed by the receiving hospital, along with visa processing. Patients already on an active treatment plan, like Rachel's, are typically prioritized for faster scheduling to avoid gaps in care.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
